Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.49 |
| ▸ | GRM5 | P41594 | 9/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459443 | 0.86 | GRM1 (0.54) | GRM1GRM5TNK2PDK4NAMPT | |
| SCHEMBL22328960 | 0.84 | GRM1 (0.51) | GRM1GRM5TNK2CDK9CCNT1 | |
| SCHEMBL17222886 | 0.83 | NAMPT (0.52) | GRM1GRM5PDK4NAMPT | |
| SCHEMBL4152429 | 0.82 | GRM1 (0.54) | GRM1GRM5WNT3ACDK9CCNT1 | |
| SCHEMBL24962318 | 0.79 | GRM1 (0.52) | GRM1GRM5TNK2PDK4NAMPT | |
| SCHEMBL4458384 | 0.79 | GRM1 (0.54) | GRM1GRM5TNK2WNT3APDE10A | |
| SCHEMBL12537891 | 0.79 | GRM1 (0.51) | GRM1GRM5TNK2PDE10APDK4 | |
| SCHEMBL12537915 | 0.79 | GRM1 (0.53) | GRM1GRM5TNK2PDE10APDK4 | |
| SCHEMBL18326659 | 0.78 | NAMPT (0.49) | GRM1GRM5CDK9CCNT1PDK4 | |
| SCHEMBL2297459 | 0.78 | NAMPT (0.58) | GRM1GRM5TNK2PDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| WO-2007100610-A2 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | CXCR3, CXCR1, CXCR5 | GRM1 337/4885GRM5 175/4885TNK2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.